Comparative Pharmacology
Head-to-head clinical analysis: LATISSE versus ZIOPTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATISSE versus ZIOPTAN.
LATISSE vs ZIOPTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It increases the growth of eyelashes by prolonging the anagen (growth) phase and increasing the number of hairs. The exact molecular mechanism is thought to involve binding to prostamide receptors, leading to modulation of intracellular signaling pathways that regulate hair follicle cycling.
ZIOPTAN (tafluprost) is a prostaglandin analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
One drop applied to the upper eyelid margin at the base of the eyelashes once daily using the provided sterile applicators.
250 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life of bimatoprost in plasma is approximately 45 minutes (range 30-60 minutes) after topical ocular application in humans. This short half-life reflects rapid systemic clearance, but the drug's ocular hypotensive effect persists for 24 hours due to tissue binding.
Terminal elimination half-life is approximately 2.8 to 4.5 hours in patients with normal renal function; no clinically significant accumulation occurs with twice-daily dosing.
Primarily renal elimination of metabolites; less than 5% of unchanged bimatoprost is excreted in urine. Fecal excretion accounts for approximately 25% of the dose, predominantly as metabolites. Biliary excretion is minimal.
Primarily renal excretion of unchanged drug (approximately 70-80% of an administered dose recovered in urine over 48 hours); biliary/fecal excretion accounts for 13% to 20% as parent drug and metabolites.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog